Novartis International AG
At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Novartis is structured to deliver innovative products, exploit global scale, and respond to new opportunities and risks. Our businesses - Innovative Medicines, Alcon and Sandoz - are supported by functional organizations with global scale. Research and development (R&D) is at the core of our company and central to the Novartis strategy.
Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. From beginnings in the production of synthetic fabric dyes, the companies that eventually became Novartis branched out into producing chemicals and ultimately pharmaceuticals.
The history of Novartis traces the converging destinies of three companies: Geigy, a chemicals and dyes trading company founded in Basel, Switzerland in the middle of the 18th century; Ciba, which began producing dyes in 1859; and Sandoz, a chemical company founded in Basel in 1886.
These companies shared a common trait which lives on at Novartis: a passion for developing and marketing new products that contribute to human progress through advances in science and health. Building on this heritage, today Novartis focuses its innovation prowess on addressing the unmet needs of patients worldwide.
Our mission is to discover new ways to improve and extend people's lives.
We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to provide a shareholder return that rewards those who invest their money, time and ideas in our company.
Our vision is to be a trusted leader in changing the practice of medicine.
Strong values define our culture and help us execute the Novartis strategy in line with our mission and vision.
We have introduced Values and Behaviors that describe the professional behaviors we expect from our employees. These values were selected by the Executive Committee of Novartis – with input from associates worldwide – and form an integral part of the framework we use to recruit people, develop them and assess and reward their performance. We will hold ourselves to account against these values and behaviors.
These values and behaviors are:
by experimenting and delivering solutions
by taking pride in doing ordinary things extraordinarily well
by championing high performing teams with diversity and inclusion
by prioritizing and making things happen with urgency
by speaking up, giving and receiving feedback
by advocating and applying high ethical standards every day
We believe Novartis is well prepared for a world with a growing, aging population and continuously evolving healthcare needs. We have a clear mission, focused strategy and strong culture, all of which we expect will support the creation of value over the long term for our company, our shareholders and society.
Our strategy is to use science-based innovation to deliver better patient outcomes. We aim to lead in growing areas of healthcare.
We believe innovation that produces breakthrough medicines and products will be more important than ever in the healthcare industry in the coming years. We maintain substantial investment in research and development (R&D) aimed at areas of unmet medical need. Our product pipeline is fed by a distinctive research and clinical approach that focuses on scientific advances before market potential.
Our R&D strategy is to continue reinforcing therapeutic areas where we are already strong – including oncology, cardiovascular, eye care, biosimilars and neuroscience – and to expand into new disease areas that we believe are ripe for innovation, such as immuno-oncology, aging and regenerative medicine, and infectious diseases.
Better patient outcomes
We seek to develop medicines and products that can produce positive real-world outcomes for patients and healthcare providers. The benefits can range from improving the cost-effectiveness of high-quality care to prolonging lives. We are developing services and technologies to augment the benefits of our core products, often in collaboration with healthcare providers and technology companies.
Lead in growing areas of healthcare
We aim to develop innovative products in growing areas of healthcare where we can make a real difference. We focus on patented medicines, generic medicines and eye care – segments where we have the innovation power and global scale necessary to compete effectively. At the same time, we are expanding our presence in the emerging markets of Asia, Africa and Latin America, where there is fast-growing demand for access to high- quality medicines and healthcare.